HomeCLLS • NASDAQ
add
Cellectis SA
$4.68
Makalipas ang Oras ng Trabaho:(0.00%)0.00
$4.68
Sarado: Dis 12, 4:30:00 PM GMT-5 · USD · NASDAQ · Disclaimer
Nakaraang pagsara
$5.22
Sakop ng araw
$4.59 - $5.05
Sakop ng taon
$1.10 - $5.48
Market cap
345.42M USD
Average na Volume
118.95K
P/E ratio
-
Dividend yield
-
Mga Financial
Income Statement
Kita
Net na kita
| (USD) | Set 2025info | Y/Y na pagbabago |
|---|---|---|
Kita | 37.16M | 105.89% |
Gastos sa pagpapatakbo | 29.12M | 1.05% |
Net na kita | 589.00K | 102.55% |
Net profit margin | 1.58 | 101.24% |
Kita sa bawat share | 0.02 | 109.09% |
EBITDA | 11.16M | 239.56% |
Aktuwal na % ng binabayarang buwis | — | — |
Balance Sheet
Kabuuang asset
Kabuuang sagutin
| (USD) | Set 2025info | Y/Y na pagbabago |
|---|---|---|
Cash at mga panandaliang investment | 52.24M | -67.16% |
Kabuuang asset | 343.04M | -13.35% |
Kabuuang sagutin | 242.57M | -8.96% |
Kabuuang equity | 100.48M | — |
Natitirang share | 72.33M | — |
Presyo para makapag-book | 3.76 | — |
Return on assets | 5.77% | — |
Return on capital | 10.65% | — |
Cash Flow
Net change in cash
| (USD) | Set 2025info | Y/Y na pagbabago |
|---|---|---|
Net na kita | 589.00K | 102.55% |
Cash mula sa mga operasyon | -1.57M | 73.05% |
Cash mula sa pag-invest | -3.44M | -115.41% |
Cash mula sa financing | -4.26M | -1.00% |
Net change in cash | -7.57M | -175.32% |
Malayang cash flow | -9.76M | -141.30% |
Tungkol
Cellectis is a French biopharmaceutical company. It develops genome-edited chimeric antigen receptor T-cell technologies for cancer immunotherapy. It has offices in Paris, New York City, and Raleigh, North Carolina. Wikipedia
Itinatag
1999
Website
Mga Empleyado
219
